Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. News
  7. Summary
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ERYTECH Pharma S A : Wins US FDA's Fast Track For Acute Lymphocytic Leukemia Treatment

07/30/2021 | 12:53am EDT


ę MT Newswires 2021
All news about ERYTECH PHARMA S.A.
11:25aEuropean ADRs Move Higher in Tuesday Trading
MT
09:52aERYTECH PHARMA S A : ▪TRYbeCA-1, Phase 3 trial of eryaspase in second-line metastati..
PU
09/20ERYTECH PHARMA S A : Provides Business Update and Reports Financial Results for the First ..
AQ
09/20ERYTECH PHARMA S A : I.CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL..
PU
09/20European ADRs Move Sharply Lower in Monday Trading
MT
09/17ERYTECH PHARMA S A : to Host on September 21, 2021 Second Quarter 2021 conference call and..
PU
09/15ERYTECH PHARMA S A : to Host on September 21, 2021 Second Quarter 2021 conference call and..
AQ
09/13European ADRs Rise 1% Monday as Energy Giants Gain, Pharma Retreats
MT
09/07GLOBAL MARKETS LIVE : Ryanair, Hyundai, Adecco, Goldman Sachs, JD.com...
09/06ERYTECH PHARMA S A : to Present at the H.C. Wainwright 23rd Annual Global Investment Confe..
GL
More news
Financials
Sales 2021 9,79 M 11,5 M 11,5 M
Net income 2021 -65,1 M -76,3 M -76,3 M
Net Debt 2021 16,1 M 18,9 M 18,9 M
P/E ratio 2021 -1,33x
Yield 2021 -
Capitalization 144 M 169 M 169 M
EV / Sales 2021 16,4x
EV / Sales 2022 5,25x
Nbr of Employees 206
Free-Float 88,9%
Chart ERYTECH PHARMA S.A.
Duration : Period :
ERYTECH Pharma S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERYTECH PHARMA S.A.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 5,20 €
Average target price 14,50 €
Spread / Average Target 179%
EPS Revisions
Managers and Directors
Gil Beyen Chief Executive Officer & Director
Eric Soyer Chief Operating & Financial Officer
Jean-Paul Kress Chairman
Iman El-Hariry Chief Medical Officer
Stewart Craig Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
ERYTECH PHARMA S.A.-26.86%183
GILEAD SCIENCES, INC.21.80%88 970
BIONTECH SE315.86%81 878
WUXI APPTEC CO., LTD.35.75%69 413
REGENERON PHARMACEUTICALS32.66%66 632
VERTEX PHARMACEUTICALS-21.44%48 168